Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Opioid Induced Constipation (OIC) Drugs Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Opioid Induced Constipation (OIC) Drugs Market Status and Forecast (2016-2027)
      • 1.3.2 Global Opioid Induced Constipation (OIC) Drugs Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Opioid Induced Constipation (OIC) Drugs Supply by Company

    • 2.1 Global Opioid Induced Constipation (OIC) Drugs Sales Volume by Company
    • 2.2 Global Opioid Induced Constipation (OIC) Drugs Sales Value by Company
    • 2.3 Global Opioid Induced Constipation (OIC) Drugs Price by Company
    • 2.4 Opioid Induced Constipation (OIC) Drugs Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Opioid Induced Constipation (OIC) Drugs Market Status by Category

    • 3.1 Opioid Induced Constipation (OIC) Drugs Category Introduction
      • 3.1.1 Lubiprostone
      • 3.1.2 Methyl Naltrexone Bromide
      • 3.1.3 Naldemedine
      • 3.1.4 Alvimopan
      • 3.1.5 Others
    • 3.2 Global Opioid Induced Constipation (OIC) Drugs Market by Category
      • 3.2.1 Global Opioid Induced Constipation (OIC) Drugs Sales Volume by Category (2016-2021)
      • 3.2.2 Global Opioid Induced Constipation (OIC) Drugs Sales Value by Category (2016-2021)
      • 3.2.3 Global Opioid Induced Constipation (OIC) Drugs Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Opioid Induced Constipation (OIC) Drugs Market Status by End User/Segment

    • 4.1 Opioid Induced Constipation (OIC) Drugs Segment by End User/Segment
      • 4.1.1 Hospital Pharmacies
      • 4.1.2 Retail Pharmacies
      • 4.1.3 Online Pharmacies
    • 4.2 Global Opioid Induced Constipation (OIC) Drugs Market by End User/Segment
      • 4.2.1 Global Opioid Induced Constipation (OIC) Drugs Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Opioid Induced Constipation (OIC) Drugs Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Opioid Induced Constipation (OIC) Drugs Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Opioid Induced Constipation (OIC) Drugs Market Status by Region

    • 5.1 Global Opioid Induced Constipation (OIC) Drugs Market by Region
      • 5.1.1 Global Opioid Induced Constipation (OIC) Drugs Sales Volume by Region
      • 5.1.2 Global Opioid Induced Constipation (OIC) Drugs Sales Value by Region
    • 5.2 North America Opioid Induced Constipation (OIC) Drugs Market Status
    • 5.3 Europe Opioid Induced Constipation (OIC) Drugs Market Status
    • 5.4 Asia Pacific Opioid Induced Constipation (OIC) Drugs Market Status
    • 5.5 Central & South America Opioid Induced Constipation (OIC) Drugs Market Status
    • 5.6 Middle East & Africa Opioid Induced Constipation (OIC) Drugs Market Status

    6 North America Opioid Induced Constipation (OIC) Drugs Market Status

    • 6.1 North America Opioid Induced Constipation (OIC) Drugs Market by Country
      • 6.1.1 North America Opioid Induced Constipation (OIC) Drugs Sales Volume by Country (2016-2021)
      • 6.1.2 North America Opioid Induced Constipation (OIC) Drugs Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Opioid Induced Constipation (OIC) Drugs Market Status

    • 7.1 Europe Opioid Induced Constipation (OIC) Drugs Market by Country
      • 7.1.1 Europe Opioid Induced Constipation (OIC) Drugs Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Opioid Induced Constipation (OIC) Drugs Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Opioid Induced Constipation (OIC) Drugs Market Status

    • 8.1 Asia Pacific Opioid Induced Constipation (OIC) Drugs Market by Country
      • 8.1.1 Asia Pacific Opioid Induced Constipation (OIC) Drugs Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Opioid Induced Constipation (OIC) Drugs Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Opioid Induced Constipation (OIC) Drugs Market Status

    • 9.1 Central & South America Opioid Induced Constipation (OIC) Drugs Market by Country
      • 9.1.1 Central & South America Opioid Induced Constipation (OIC) Drugs Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Opioid Induced Constipation (OIC) Drugs Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Opioid Induced Constipation (OIC) Drugs Market Status

    • 10.1 Middle East & Africa Opioid Induced Constipation (OIC) Drugs Market by Country
      • 10.1.1 Middle East & Africa Opioid Induced Constipation (OIC) Drugs Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Opioid Induced Constipation (OIC) Drugs Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Opioid Induced Constipation (OIC) Drugs Manufacturing Cost Analysis
    • 11.5 Opioid Induced Constipation (OIC) Drugs Sales Channel and Distributors Analysis
      • 11.5.1 Opioid Induced Constipation (OIC) Drugs Sales Channel
      • 11.5.2 Opioid Induced Constipation (OIC) Drugs Distributors
    • 11.6 Opioid Induced Constipation (OIC) Drugs Downstream Major Buyers

    12 Global Opioid Induced Constipation (OIC) Drugs Market Forecast by Category and by End User/Segment

    • 12.1 Global Opioid Induced Constipation (OIC) Drugs Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Opioid Induced Constipation (OIC) Drugs Forecast by Category
      • 12.2.1 Global Opioid Induced Constipation (OIC) Drugs Sales Volume Forecast by Category
      • 12.2.2 Global Opioid Induced Constipation (OIC) Drugs Sales Value Forecast by Category
      • 12.2.3 Global Opioid Induced Constipation (OIC) Drugs Price Forecast by Category
    • 12.3 Global Opioid Induced Constipation (OIC) Drugs Forecast by End User/Segment
      • 12.3.1 Global Opioid Induced Constipation (OIC) Drugs Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Opioid Induced Constipation (OIC) Drugs Sales Value Forecast by End User/Segment
      • 12.3.3 Global Opioid Induced Constipation (OIC) Drugs Price Forecast by End User/Segment

    13 Global Opioid Induced Constipation (OIC) Drugs Market Forecast by Region/Country

    • 13.1 Global Opioid Induced Constipation (OIC) Drugs Market Forecast by Region (2022-2027)
      • 13.1.1 Global Opioid Induced Constipation (OIC) Drugs Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Opioid Induced Constipation (OIC) Drugs Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Theravance Biopharma Inc
      • 14.1.1 Company Information
      • 14.1.2 Opioid Induced Constipation (OIC) Drugs Product Introduction
      • 14.1.3 Theravance Biopharma Inc Opioid Induced Constipation (OIC) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Takeda Pharmaceutical Company Limited
      • 14.2.1 Company Information
      • 14.2.2 Opioid Induced Constipation (OIC) Drugs Product Introduction
      • 14.2.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Sucampo Pharmaceuticals
      • 14.3.1 Company Information
      • 14.3.2 Opioid Induced Constipation (OIC) Drugs Product Introduction
      • 14.3.3 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Shionogi & Co., Ltd
      • 14.4.1 Company Information
      • 14.4.2 Opioid Induced Constipation (OIC) Drugs Product Introduction
      • 14.4.3 Shionogi & Co., Ltd Opioid Induced Constipation (OIC) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 S.L.A. Pharma AG
      • 14.5.1 Company Information
      • 14.5.2 Opioid Induced Constipation (OIC) Drugs Product Introduction
      • 14.5.3 S.L.A. Pharma AG Opioid Induced Constipation (OIC) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Purdue Pharma
      • 14.6.1 Company Information
      • 14.6.2 Opioid Induced Constipation (OIC) Drugs Product Introduction
      • 14.6.3 Purdue Pharma Opioid Induced Constipation (OIC) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Progenics Pharmaceuticals Inc
      • 14.7.1 Company Information
      • 14.7.2 Opioid Induced Constipation (OIC) Drugs Product Introduction
      • 14.7.3 Progenics Pharmaceuticals Inc Opioid Induced Constipation (OIC) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Pfizer
      • 14.8.1 Company Information
      • 14.8.2 Opioid Induced Constipation (OIC) Drugs Product Introduction
      • 14.8.3 Pfizer Opioid Induced Constipation (OIC) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Ono Pharmaceutical Co., Ltd
      • 14.9.1 Company Information
      • 14.9.2 Opioid Induced Constipation (OIC) Drugs Product Introduction
      • 14.9.3 Ono Pharmaceutical Co., Ltd Opioid Induced Constipation (OIC) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Nektar Therapeutics
      • 14.10.1 Company Information
      • 14.10.2 Opioid Induced Constipation (OIC) Drugs Product Introduction
      • 14.10.3 Nektar Therapeutics Opioid Induced Constipation (OIC) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Mundipharma International Limited
    • 14.12 Ironwood Pharmaceuticals Inc
    • 14.13 Daiichi Sankyo Co Ltd
    • 14.14 Daewoong Pharmaceutical
    • 14.15 Cosmo Pharmaceuticals SA
    • 14.16 C.B. Fleet Company
    • 14.17 Bausch Health
    • 14.18 Allergan Plc

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Opioid Induced Constipation (OIC) Drugs market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Opioid Induced Constipation (OIC) Drugs market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Lubiprostone
      Methyl Naltrexone Bromide
      Naldemedine
      Alvimopan
      Others

      Segmented by End User/Segment
      Hospital Pharmacies
      Retail Pharmacies
      Online Pharmacies

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Theravance Biopharma Inc
      Takeda Pharmaceutical Company Limited
      Sucampo Pharmaceuticals
      Shionogi & Co., Ltd
      S.L.A. Pharma AG
      Purdue Pharma
      Progenics Pharmaceuticals Inc
      Pfizer
      Ono Pharmaceutical Co., Ltd
      Nektar Therapeutics
      Mundipharma International Limited
      Ironwood Pharmaceuticals Inc
      Daiichi Sankyo Co Ltd
      Daewoong Pharmaceutical
      Cosmo Pharmaceuticals SA
      C.B. Fleet Company
      Bausch Health
      Allergan Plc
      Buy now